Top Story Today
GSK Bets $10.6 Billion on Two Lung Cancer Drugs That Haven't Earned a Dime
GSK is acquiring Nuvalent for $10.6 billion in all cash, paying a 40% premium for two precision lung cancer drugs that have zero commercial revenue. The first, zidesamtinib (targeting ROS1 mutations), has an FDA decision date in September 2026. The second, neladalkib (targeting ALK mutations), hasn't even filed its application yet. It's GSK's largest acquisition ever, driven by a looming patent cliff and the company's sprint to reach 40 billion pounds in annual sales by 2031. The NSCLC market is projected to hit $80 billion by 2035, and GSK is buying a two-for-one combo meal in the fastest-growing segment.
Why it matters: This deal crystallizes Big Pharma's patent cliff panic and its pivot toward precision oncology. With four acquisitions totaling $14.7 billion across 2025-2026, GSK is essentially rebuilding its pipeline in real time, betting that biomarker-driven cancer therapies will replace the blockbuster model that's running out of clock.
Read more →AI Is Having Its Moment
An Algorithm's Psoriasis Pill Just Embarrassed the Reigning Champ
Takeda's zasocitinib, a TYK2 inhibitor designed through AI-driven molecular modeling, delivered more than 2.5 times the complete skin clearance rate of BMS's Sotyktu in a head-to-head Phase 3 trial. Both drugs target the exact same protein in the exact same spot; the AI just designed a key that fits better, with over one-million-fold selectivity for TYK2. Takeda plans to file for FDA approval with a potential U.S. launch in early 2027.
Read more →Roche Just Bought the AI That Reads Your Cancer Slides
Roche is paying up to $1.05 billion for PathAI, whose software uses artificial intelligence to analyze cancer tissue slides. The deal gives Roche control of the full diagnostic stack, from scanners to AI-generated diagnosis, with the real prize being AI-powered companion diagnostics that match patients to the right cancer drugs.
Read more →Roche Advances the First Drug Target No Human Discovered
The first AI-discovered drug target from Roche's $12 billion Recursion partnership just moved into a formal discovery program for neurodegenerative disease. Recursion grew over one trillion human neurons and captured tens of millions of cellular images to find it. In a field with a 99% failure rate, it's either a breakthrough or the most expensive science experiment in history.
Read more →Deals and M&A
Incyte Drops $1.25 Billion on a Disease Most People Can't Pronounce
Incyte is acquiring Vega Therapeutics for up to $2 billion to get VGA039, a first-in-class antibody for von Willebrand disease that showed an 81% reduction in bleeding rates in early trials. The real motivation: Jakafi's patent cliff is approaching, and Incyte needs a new franchise. Analysts peg VGA039's peak sales at roughly $1 billion by 2036.
Read more →Clinical and Regulatory
The First New Class of ADHD Drug in 60 Years Just Got Approved
The FDA approved centanafadine (Simtriyo), the first triple reuptake inhibitor for ADHD, covering adults and kids six and up. It hits norepinephrine, dopamine, and serotonin, that third lever being new territory for ADHD treatment. It's not stronger than stimulants, but for patients who can't tolerate them or struggle with co-occurring anxiety, it fills a gap that's been open for decades.
Read more →Moderna's mRNA Flu Shot Clears Its Biggest Hurdle Yet
The FDA's vaccine advisory committee voted 9-0 (twice) to recommend Moderna's mFlusiva, which would become the first mRNA flu vaccine ever licensed in the U.S. In a 40,000-patient trial, it cut flu risk by 26.6% compared to standard shots. The FDA's final decision is due August 5, with doses potentially shipping for the 2026-2027 flu season.
Read more →The FDA Just Aired 14 of Pharma's Drug Rejection Letters
The FDA published 14 Complete Response Letters for the public to read. Companies used to omit roughly 85% of the FDA's concerns when describing their own rejections. Wall Street loves the transparency; small biotechs with single-asset pipelines are considerably less thrilled.
Read more →Data Security
Hackers Got Into Novo Nordisk's Clinical Trials, Not Just Its Emails
Hackers accessed clinical trial patient data at Novo Nordisk, copying biomarkers, health records, and lifestyle details from active studies. A group called FulcrumSec claims 1.3 terabytes stolen and demanded $25 million. Novo says the data was pseudonymized, but research shows re-identification success rates between 26% and 34% on similar datasets. No pipeline disruption so far, but the breach exposes how vulnerable trial data really is.
Read more →